Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus TOBRAMYCIN AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus TOBRAMYCIN AND DEXAMETHASONE.
GENTAFAIR vs TOBRAMYCIN AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Tobramycin: aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA. Dexamethasone: corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
1-2 drops of suspension into the conjunctival sac every 4-6 hours; in severe cases, every 2 hours initially, then taper.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Tobramycin: 2-3 hours in patients with normal renal function; prolonged (24-60 hours) in renal impairment. Dexamethasone: 3-5 hours in adults; prolonged in hepatic impairment.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Tobramycin is eliminated primarily by the kidneys via glomerular filtration, with 80-90% of an absorbed dose excreted unchanged in urine over 24 hours; minor biliary/fecal excretion (<1%). Dexamethasone is metabolized in the liver and excreted in urine (65%) and feces (35%) as metabolites.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic